<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/17381B7D-83F4-45CC-874A-52B245063BA7"><gtr:id>17381B7D-83F4-45CC-874A-52B245063BA7</gtr:id><gtr:name>Head Office</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EAF17943-4FDF-4E08-A8D2-281D7130987C"><gtr:id>EAF17943-4FDF-4E08-A8D2-281D7130987C</gtr:id><gtr:name>Birkbeck, University of London</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/17381B7D-83F4-45CC-874A-52B245063BA7"><gtr:id>17381B7D-83F4-45CC-874A-52B245063BA7</gtr:id><gtr:name>Head Office</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EAF17943-4FDF-4E08-A8D2-281D7130987C"><gtr:id>EAF17943-4FDF-4E08-A8D2-281D7130987C</gtr:id><gtr:name>Birkbeck, University of London</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/792C10D6-F2AC-422B-988F-CAD03EFC196A"><gtr:id>792C10D6-F2AC-422B-988F-CAD03EFC196A</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Collinge</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8AE8D121-C42A-47C7-A4B1-F5FDE2B1C413"><gtr:id>8AE8D121-C42A-47C7-A4B1-F5FDE2B1C413</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>Clarke</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U123160656"><gtr:id>47784FCD-73BE-4F20-8EC5-732AAB072C72</gtr:id><gtr:title>Structural studies of prion proteins and their ligand interactions</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U123160656</gtr:grantReference><gtr:abstractText>The central basic research aim of the Unit remains determining of the atomic structures of the infectious agent. Prions consist of abnormal forms of one of the bodys own proteins, the prion protein, which has changed its shape and which then clumps together to form aggregates that build up in the brain. Highly specialised facilities and expertise have been developed at the Unit to study prion structure. Genetic engineering of bacteria has been used to make large quantities of various prion proteins to study their structure and also to learn how infectious prions can be made synthetically. Understanding the molecular mechanism of prion replication will be of major importance well beyond prion biology and disease. Such mechanisms will be of wide interest with respect to a range of diseases know to involve the bodys proteins changing their shape and forming aggregates, which includes most of the commoner degenerative brain diseases (such as Alzheimers disease and Parkinsons disease).</gtr:abstractText><gtr:technicalSummary>Prion diseases such as variant CJD and BSE involve accumulation of misfolded forms of normally benign host protein (PrPC) in the tissues of the brain. These misfolded, disease-associated forms are known as PrPSc. To understand this switch in structure and to generate material for work on diagnostic and therapeutic aspects of the disease, we have developed recombinant methods for expressing PrP in E. coli. The production of large quantities of protein have allowed us to make made significant progress in studying the folding and unfolding pathways of human prion protein leading to the identification of several conformational isomers of the protein, in particular ?-PrP, which shares many biophysical characteristics with PrPSc. When ?-PrP is presented as an antigen for the creation of anti-PrP monoclonal antibodies, the resultant antibodies have affinity for native PrPSc. Defining the folding pathway of PrP is crucial to understanding the events leading to the formation of PrPSc. In the case of other amyloidogenic proteins partially structured folding intermediates have been implicated in the destructive aggregation reactions leading to disease. Using NMR techniques to define backbone amide exchange rates we have demonstrated that PrP, unlike other amyloidogenic proteins, does not populate any folding intermediates. This finding portends that native PrPC must unfold before rearrangement to the PrPSc conformation can occur. This finding has been of particular importance in the design of therapeutic strategies for prion disease. Our efforts in screening for potential anti-prion drugs have focused upon the identification of compounds that stabilise PrPC, and hence reduce the pool of unfolded molecules available for conversion to PrPSc.The biological function of PrP remains a subject of much debate; with suggestions that it may play a role in protection from oxidative stress or participate in copper homeostasis. The hypothesis that PrP may be a cupro-protein in vivo has lacked convincing support due to the apparent low affinity with which the protein binds divalent metal ions. Using a combination of fluorescence and NMR techniques we have fully characterized the affinity and location of such sites. A key objective for the future is to establish a synthetic source of prion infectivity. Although current work indicates that recombinant material may be rendered infectious, the titre appears low suggesting only a minor component is responsible. To mimic the situation in vivo more closely, mature, eukaryotically expressed PrP possessing a GPI anchor and carbohydrate moieties is required. The conversion of this material into a form that possesses high titre prion infectivity would represent the essential model by which the molecular pathogenesis of prion disease could be dissected. The determination of ?-PrP structure is a key element of furthering our understanding of the conformational events that underlie prion diseases. In addition to the solution structure of soluble ?-PrP we wish to map the interaction surfaces that dictate the ordered packing of PrP into fibrillar structures. Structural information on the nature of sub-unit interfaces in fibrillar PrP may assist in the rational design of therapeutics.</gtr:technicalSummary><gtr:fund><gtr:end>2017-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1999-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>6657117</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biochemistry Bristol</gtr:department><gtr:description>Molecular Modelling</gtr:description><gtr:id>5C157D34-6723-4E89-BE45-2C4E4CBA90FC</gtr:id><gtr:impact>20876144</gtr:impact><gtr:outcomeId>e6u8YG7MLZW-1</gtr:outcomeId><gtr:partnerContribution>Provision of computing hardware and software, Intellectual input, publications</gtr:partnerContribution><gtr:piContribution>Access to relevant data. Intellectual input into collaborator's research.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Birkbeck, University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Biological Sciences</gtr:department><gtr:description>Electron Microscopy</gtr:description><gtr:id>936D2CB7-7485-4463-BBBA-D5144AADEC67</gtr:id><gtr:impact>16473369</gtr:impact><gtr:outcomeId>2B5D9093807-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input, Access to EM Equipment &amp;amp; Facilities, Training of Staff in acquisition of EM data, Publications</gtr:partnerContribution><gtr:piContribution>Access to relevant data, Intellectual input into collaborator's research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Daresbury Laboratory</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Protein Crystallography</gtr:description><gtr:id>94B838F5-5D1F-474C-99E2-2803501A1A04</gtr:id><gtr:impact>19204296</gtr:impact><gtr:outcomeId>2482300D341-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input, Access to Equipment &amp;amp; Facilities, Training of Staff, Publications</gtr:partnerContribution><gtr:piContribution>Access to relevant data, Intellectual input into collaborator's research</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sheffield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Molecular Biology and Biotechnology</gtr:department><gtr:description>Biomolecular NMR</gtr:description><gtr:id>7A6E05F5-D685-435D-90A3-722CA75DD75E</gtr:id><gtr:impact>19369250 19321423 16925523 16824036 20876144 20718410</gtr:impact><gtr:outcomeId>46D4890A15C-1</gtr:outcomeId><gtr:partnerContribution>Provision of NMR spectrometers &amp;amp; Facilities, Intellectual input Training of Staff Publications</gtr:partnerContribution><gtr:piContribution>Access to relevant data. Access to AUC facilities. Intellectual input into collaborator's research. Laboratory space and part-supervision for a PhD student</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biosciences</gtr:department><gtr:description>Analytical Ultracentrifugation</gtr:description><gtr:id>82C84E66-032F-4221-8263-C254BE3FACA1</gtr:id><gtr:impact>19369250</gtr:impact><gtr:outcomeId>91A4DBDE1A8-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input Training of Staff Publications</gtr:partnerContribution><gtr:piContribution>Access to relevant data, Intellectual input into collaborator's research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biochemistry Bristol</gtr:department><gtr:description>Lipid/Membrane Associations</gtr:description><gtr:id>AAF4E3E7-6222-480B-B337-ECD6B03D43A6</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>m6CYpVSwTRf-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input, Access to Equipment &amp;amp; Facilities, Training of Staff in manipulation of reconstituted lipid</gtr:partnerContribution><gtr:piContribution>Access to relevant data, Intellectual input into collaborator's research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8B1C1C3F-7A83-4470-9596-CDA135261E20</gtr:id><gtr:title>Conformational properties of beta-PrP.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15445b32afbe19ecababb3bb975097f8"><gtr:id>15445b32afbe19ecababb3bb975097f8</gtr:id><gtr:otherNames>Hosszu LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>8068332A63D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10105B5D-D149-4130-9549-1EE7591173D3</gtr:id><gtr:title>Prion propagation and toxicity in vivo occur in two distinct mechanistic phases.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c101120111e9f19df81b4f0bdae6dff"><gtr:id>8c101120111e9f19df81b4f0bdae6dff</gtr:id><gtr:otherNames>Sandberg MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>tA2hgAiHEMu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D123981D-675B-4D4B-B937-EA19417DF716</gtr:id><gtr:title>Pharmacological chaperone for the structured domain of human prion protein.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47d5e240428d904766fabe26c08463fd"><gtr:id>47d5e240428d904766fabe26c08463fd</gtr:id><gtr:otherNames>Nicoll AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>jthWNGwfcK6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>298E48BC-BF9B-4997-BB9F-7FE86CC60B50</gtr:id><gtr:title>Multiple forms of copper (II) co-ordination occur throughout the disordered N-terminal region of the prion protein at pH 7.4.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2b398fefefb405c70b3a85a98965243"><gtr:id>c2b398fefefb405c70b3a85a98965243</gtr:id><gtr:otherNames>Wells MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>7B0875265A3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F434CD5A-674D-4B24-83DF-A9D4D7DE0191</gtr:id><gtr:title>Detection and characterization of proteinase K-sensitive disease-related prion protein with thermolysin.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53740aa86cab452a475ba97e3f46e1b0"><gtr:id>53740aa86cab452a475ba97e3f46e1b0</gtr:id><gtr:otherNames>Cronier S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>WM1cB2r4jrh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A17C758F-4E2E-4C8B-AB62-5597F5C14E9F</gtr:id><gtr:title>A systematic investigation of production of synthetic prions from recombinant prion protein.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b2740857e0a6a774e56992f6a12381e"><gtr:id>7b2740857e0a6a774e56992f6a12381e</gtr:id><gtr:otherNames>Schmidt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>56dda4474c1d22.55002362</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD05F2E8-5D97-4F9A-9B23-BF49B344A032</gtr:id><gtr:title>Highly sensitive, quantitative cell-based assay for prions adsorbed to solid surfaces.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d7b7e2fe78d5e2742820eea3aa14ddd"><gtr:id>5d7b7e2fe78d5e2742820eea3aa14ddd</gtr:id><gtr:otherNames>Edgeworth JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>68E7CB90600</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F9EBC13-DEC9-432D-8537-2CA2C496DD9B</gtr:id><gtr:title>The H187R mutation of the human prion protein induces conversion of recombinant prion protein to the PrP(Sc)-like form.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15445b32afbe19ecababb3bb975097f8"><gtr:id>15445b32afbe19ecababb3bb975097f8</gtr:id><gtr:otherNames>Hosszu LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>cbx6WA4YNoR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50C413E0-553A-48B7-953C-F0DF807AF309</gtr:id><gtr:title>Crystal structure of human prion protein bound to a therapeutic antibody.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02ad916747b020af716f1fe16ba777e9"><gtr:id>02ad916747b020af716f1fe16ba777e9</gtr:id><gtr:otherNames>Antonyuk SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>65DAFFC195C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9726494-C467-41FA-B6BA-F50B71797758</gtr:id><gtr:title>Interaction between prion protein and toxic amyloid ? assemblies can be therapeutically targeted at multiple sites.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f87882018fcf76fd424390a5a57f6bed"><gtr:id>f87882018fcf76fd424390a5a57f6bed</gtr:id><gtr:otherNames>Freir DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>bsHBX2hrVKF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>246512B2-4568-4F04-8A45-B2FB42401465</gtr:id><gtr:title>Beta-PrP form of human prion protein stimulates production of monoclonal antibodies to epitope 91-110 that recognise native PrPSc.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a01d25033815bed5d0d7bc3dc096d32c"><gtr:id>a01d25033815bed5d0d7bc3dc096d32c</gtr:id><gtr:otherNames>Khalili-Shirazi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>B027DE4054F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BCB14A3-5DDC-4407-ABB3-3CE3C49F6654</gtr:id><gtr:title>A reassessment of copper(II) binding in the full-length prion protein.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2b398fefefb405c70b3a85a98965243"><gtr:id>c2b398fefefb405c70b3a85a98965243</gtr:id><gtr:otherNames>Wells MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>1EA38BE5039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A51C987-DC34-4E3E-B84C-851EF236A532</gtr:id><gtr:title>Elongated oligomers assemble into mammalian PrP amyloid fibrils.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e073b120372c44bd19d0a6219bb4623"><gtr:id>3e073b120372c44bd19d0a6219bb4623</gtr:id><gtr:otherNames>Tattum MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>86F53F8628F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>457C9617-C80C-44A8-B038-95F37C590FAB</gtr:id><gtr:title>Disease-associated prion protein oligomers inhibit the 26S proteasome.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b2c9e84a2d8cce8f9ac2c9beec0c386"><gtr:id>0b2c9e84a2d8cce8f9ac2c9beec0c386</gtr:id><gtr:otherNames>Kristiansen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>9FCDA667964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>017F108B-AC3E-4B54-AF32-8B617D9D1377</gtr:id><gtr:title>A novel prion protein variant in a patient with semantic dementia.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4eddb0cc7499466ab802a8e6d83d23b"><gtr:id>f4eddb0cc7499466ab802a8e6d83d23b</gtr:id><gtr:otherNames>Kenny J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5a9692b9600763.01439316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8C7663F-2676-468F-9366-CA855EFEAC4A</gtr:id><gtr:title>Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c101120111e9f19df81b4f0bdae6dff"><gtr:id>8c101120111e9f19df81b4f0bdae6dff</gtr:id><gtr:otherNames>Sandberg MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5460a360d0a5f0.35850742</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F3BD960-2231-45FE-B756-481050ADC9E6</gtr:id><gtr:title>Rapid cell-surface prion protein conversion revealed using a novel cell system.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b4a39284abbd940f6ef1be5b6468337"><gtr:id>9b4a39284abbd940f6ef1be5b6468337</gtr:id><gtr:otherNames>Goold R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>oou948TqRhS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF61F06D-F6AC-49C1-8B3D-2E945E884774</gtr:id><gtr:title>A general model of prion strains and their pathogenicity.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a46902526a5df5054ffa4a1bb4ba33a6"><gtr:id>a46902526a5df5054ffa4a1bb4ba33a6</gtr:id><gtr:otherNames>Collinge J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>44CF8FA571F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB8191F9-69F6-4320-BDEF-E6E66CA53EC7</gtr:id><gtr:title>Removal of the glycosylphosphatidylinositol anchor from PrP(Sc) by cathepsin D does not reduce prion infectivity.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43c07010bfe3a3446b64256aded46ad8"><gtr:id>43c07010bfe3a3446b64256aded46ad8</gtr:id><gtr:otherNames>Lewis PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>B3D4636DD20</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FC9FA19-6B3C-43DE-98C0-83C20EE01CD0</gtr:id><gtr:title>Folding kinetics of the human prion protein probed by temperature jump.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f2112888dab4fb3e6b612aa777ffe44"><gtr:id>1f2112888dab4fb3e6b612aa777ffe44</gtr:id><gtr:otherNames>Hart T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>966131A6406</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AA9ECFA-0049-4C02-A967-BC483BA3BF14</gtr:id><gtr:title>N-terminal domain of prion protein directs its oligomeric association.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f4e6488aef6e1790f01c9944165d070"><gtr:id>6f4e6488aef6e1790f01c9944165d070</gtr:id><gtr:otherNames>Trevitt CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>5460a360a865f3.05266721</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95A66C99-2B50-4A97-BF65-8D5318232E0C</gtr:id><gtr:title>Inhibition of proteinase K activity by copper(II) ions.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b3c0d274c9d3ef761e989e7a43f3c0a"><gtr:id>8b3c0d274c9d3ef761e989e7a43f3c0a</gtr:id><gtr:otherNames>Stone LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>RNyKsJsNaqx</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U123160656</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>